Search peptides — top sellers first
Search peptides — top sellers first
Search peptides — top sellers first
15-18% less visceral fat in 26 weeks
Made in USA — Synthesized in our cGMP-compliant US facility
Buy 1, Get 1 Free · auto-applied
Add 2+ items to cart to activate the discount
Secure, encrypted checkout
Frequently bought together
Researchers usually add these to complete the protocol.
BAC Water · 3ml
Essential · extras
GHK-CU · 50mg
recovery
Melanotan 2 · 10mg
Tanning
Tesamorelin · 10mg
Certificate of analysis
We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.
Freedom Diagnostics
Independent analytical lab
Certificate of Analysis
RESULT · PASS
Analytical results
HPLC Chromatogram
Main peak 99.87% · other 0.13%
Alex Johnson
Principal Chemist
Scanned 2×
Know your compound
Tesamorelin is a synthetic version of GHRH, the natural signal that tells the pituitary gland to release growth hormone. It's the only GHRH analog to reach clinical study, originally developed for HIV-related belly-fat research.
What set it apart in trials: it shrank deep visceral fat while leaving surface (subcutaneous) fat and insulin sensitivity alone. Because it prompts growth hormone in natural pulses rather than flooding the system, it's one of the best-documented compounds in metabolic and body-composition research.
For research use only — not for human or veterinary use.
The research
The published findings behind this compound — the headline numbers, in plain terms, each cited to source. Preclinical results are directional (animal / in-vitro) and shown for context, not as therapeutic claims.
In phase 3 trials in people with HIV-associated lipodystrophy, deep visceral fat fell by roughly 15–18% over 26 weeks of tesamorelin.
Approximate trajectory; deep visceral adipose tissue relative to baseline.
While deep visceral fat dropped, trials reported no matching reduction in surface (subcutaneous) fat — suggesting the effect was targeted rather than general fat loss.
Relative direction of change; subcutaneous fat was not meaningfully reduced.
Pharmacology reviews report that tesamorelin raised IGF-1 by prompting growth hormone in natural pulses rather than a constant flood.
Direction of change; reported IGF-1 rise following pulsatile GH release.
In HIV-associated fatty liver disease, tesamorelin shifted hepatic gene-expression signatures tied to liver fat and fibrosis pathways.
Directional change in hepatic transcriptomic signatures; magnitudes illustrative.
Mechanism
A GHRH analogue studied for prompting growth hormone with a notably targeted effect on visceral fat.
Studied for binding the GHRH receptor to prompt natural, pulse-like growth-hormone release.
Investigated in trials for shrinking deep visceral fat while sparing surface fat and insulin sensitivity.
Researched for downstream IGF-1 signalling and effects on hepatic lipid pathways.
For research use only. Mechanisms described reflect published research literature.
The process
Synthesized
Produced under controlled manufacturing with documented, repeatable processes.
HPLC purity
An independent lab reports the exact purity of every lot — a number, never a 'passes'.
Mass-spec identity
Molecular weight confirms the exact sequence is what the label says.
COA published
The certificate is posted to the open library, by lot, before the vial ships.
Best sellers
FAQ
Common questions about Tesamorelin
The COA guarantee
Have any lot independently re-tested. If the results don't match the published certificate, we refund the order in full — no returns, no questions.
Order with coverThird-party tested
An independent, accredited lab — no commercial interest in the result.
A COA on every lot
A lot-specific certificate ships with each vial, archived by batch.
Test it yourself → refund
Re-test any batch at any lab. A mismatch is a full refund.
